Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial

Cancer Immunology, Immunotherapy

Volumn 63, Issue 2, 2014, Pages 133-145

  Guest, Ryan D ^a   Kirillova, Natalia ^a   Mowbray, Sam ^a   Gornall, Hannah ^b   Rothwell, Dominic G ^c   Cheadle, Eleanor J ^d   Austin, Eric ^e   Smith, Keith ^e   Watt, Suzanne M ^f   Kühlcke, Klaus ^g   Westwood, Nigel ^h   Thistlethwaite, Fiona ^b,i   Hawkins, Robert E ^b,i   Gilham, David E ^b  

^a Cellular Therapeutics Ltd   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d Institute of Cancer Sciences   (United Kingdom)

^e NHS BLOOD AND TRANSPLANT   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g BIONTECH AG   (Germany)

^h IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Adoptive cell therapy; Bioprocessing; Cell culture; Chimeric antigen receptor; Good manufacturing process; T cell

Indexed keywords

ADOPTIVE TRANSFER; CARCINOEMBRYONIC ANTIGEN; CHIMERIN PROTEINS; HUMANS; IMMUNOPHENOTYPING; INTERFERON-GAMMA; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84894443958     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1492-9     Document Type: Article

References (29)

1. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5(177):177ra138. doi: 10.1126/scitranslmed.3005930
2. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73. doi: 10.1126/scitranslmed.3002842
3. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119(12):2709-2720. doi: 10.1182/blood-2011-10-384388
4. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725-733. doi: 10.1056/NEJMoa1103849
5. Gilham DE, Debets R, Pule M, Hawkins RE, Abken H (2012) CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med 18(7):377-384. doi: 10.1016/j.molmed.2012.04.009
6. Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG (2012) Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother 61(7):953-962. doi: 10.1007/s00262-012-1254-0
7. Zimmermann W, Weber B, Ortlieb B, Rudert F, Schempp W, Fiebig HH, Shively JE, von Kleist S, Thompson JA (1988) Chromosomal localization of the carcinoembryonic antigen gene family and differential expression in various tumors. Cancer Res 48(9):2550-2554
8. Verhaar MJ, Chester KA, Keep PA, Robson L, Pedley RB, Boden JA, Hawkins RE, Begent RH (1995) A single chain Fv derived from a filamentous phage library has distinct tumor targeting advantages over one derived from a hybridoma. Int J Cancer 61(4):497-501. doi: 10.1002/ijc.2910610412
9. Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJ, Robson L (1996) Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 2(9):979-984. doi: 10.1038/nm0996-979
10. Mayer A, Francis RJ, Sharma SK, Tolner B, Springer CJ, Martin J, Boxer GM, Bell J, Green AJ, Hartley JA, Cruickshank C, Wren J, Chester KA, Begent RH (2006) A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clin Cancer Res 12(21):6509-6516. doi: 10.1158/1078-0432.CCR-06-0769
11. Gilham DE, O'Neil A, Hughes C, Guest RD, Kirillova N, Lehane M, Hawkins RE (2002) Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother 25(2):139-151. doi: 10.1097/00002371- 200203000-00002
12. Sheen AJ, Sherlock DJ, Irlam J, Hawkins RE, Gilham DE (2003) T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches. Br J Cancer 88(7):1119-1127. doi: 10.1038/sj.bjc.6600857
13. Hombach AA, Schildgen V, Heuser C, Finnern R, Gilham DE, Abken H (2007) T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol 178(7):4650-4657
14. Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, Irlam J, Chester KA, Kemshead JT, Shaw DM, Embleton MJ, Stern PL, Gilham DE (2005) The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 28(3):203-211. doi: 10.1097/01.cji.0000161397.96582.59
15. Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL (2012) Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol 39(3):296-304. doi: 10.1053/j.seminoncol.2012.02.010
16. Safar M, Junghans RP (2000) Interleukin 2 maintains biologic stability and sterility over prolonged time. Immunopharmacology 49(3):419-423. doi: 10.1016/S0162-3109(00)00241-1
17. Calmels B, Houze P, Hengesse JC, Ducrot T, Malenfant C, Chabannon C (2003) Preclinical evaluation of an automated closed fluid management device: Cytomate, for washing out DMSO from hematopoietic stem cell grafts after thawing. Bone Marrow Transplant 31(9):823-828. doi: 10.1038/sj.bmt.1703905
18. Fehse B, Kustikova OS, Li Z, Wahlers A, Bohn W, Beyer WR, Chalmers D, Tiberghien P, Kuhlcke K, Zander AR, Baum C (2002) A novel 'sort-suicide' fusion gene vector for T cell manipulation. Gene Ther 9(23):1633-1638. doi: 10.1038/sj.gt.3301828
19. Lamers CH, van Elzakker P, van Steenbergen SC, Sleijfer S, Debets R, Gratama JW (2008) Retronectin-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield. Cytotherapy 10(4):406-416. doi: 10.1080/14653240801982961
20. Lamers CH, Willemsen RA, Luider BA, Debets R, Bolhuis RL (2002) Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther 9(7):613-623. doi: 10.1038/sj.cgt.7700477
21. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12(20 Pt 1):6106-6115. doi: 10.1158/1078-0432.CCR-06-1183
22. Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R, Gratama JW (2013) Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 21(4):904-912. doi: 10.1038/mt.2013.17
23. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843-851. doi: 10.1038/mt.2010.24
24. Lamers CH, van Elzakker P, Langeveld SC, Sleijfer S, Gratama JW (2006) Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene. Cytotherapy 8(6):542-553. doi: 10.1080/14653240601056396
25. Gattinoni L, Klebanoff CA, Restifo NP (2012) Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 12(10):671-684. doi: 10.1038/nrc3322
26. Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, Bondanza A, Bordignon C, Peccatori J, Ciceri F, Lupo-Stanghellini MT, Mavilio F, Mondino A, Bicciato S, Recchia A, Bonini C (2013) IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121(4):573-584. doi: 10.1182/blood-2012-05-431718
27. Yang S, Ji Y, Gattinoni L, Zhang L, Yu Z, Restifo NP, Rosenberg SA, Morgan RA (2013) Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol Immunother 62(4):727-736. doi: 10.1007/s00262-012-1378-2
28. Somerville RP, Devillier L, Parkhurst MR, Rosenberg SA, Dudley ME (2012) Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE(R) bioreactor. J Transl Med 10:69. doi: 10.1186/1479-5876-10-69
29. Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, Wilson J, Dotti G, Heslop HE, Leen AM, Rooney CM (2010) Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 33(3):305-315. doi: 10.1097/CJI.0b013e3181c0c3cb